Top entities: CARB-X, Richard Alm, Anita Gashi, Italy — Ministry of Economy and Finance (Italy), United Kingdom — Department of Health and Social Care.

What category does this event fall under?

Business — classified as funding award.

What is the sentiment of coverage?

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business funding award

CARB-X Funds AdJane Gonorrhea Vaccine

Q: When did this event occur?

First reported Apr 28, 2026; last updated Apr 28, 2026.

Q: What is the market impact?

General. The funding award from CARB-X to AdJane is positive for the biotechnology and pharmaceutical markets, as it advances the development of a vaccine against gonorrhea, a significant global health challenge.

Analysis based on 7 articles · First reported Apr 28, 2026 · Last updated Apr 28, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The funding award from CARB-X to AdJane is positive for the biotechnology and pharmaceutical markets, as it advances the development of a vaccine against gonorrhea, a significant global health challenge. This could lead to future revenue streams for AdJane and potentially other companies involved in the vaccine's development and distribution.

Biotechnology Pharmaceuticals

Event Summary

CARB-X has awarded US$2.6 million to AdJane to further the development of its nOMV platform-derived vaccine candidate for the prevention of Neisseria gonorrhoeae infections, which cause gonorrhea. This funding aims to combat rising antimicrobial resistance and address global health challenges. AdJane's nOMV platform, which has completed a Phase I clinical trial, uses a heterologous approach to elicit a broad-spectrum immune response. This award is a continuation of previous support from CARB-X for AdJane's gonorrhea vaccine development. CARB-X, a global non-profit partnership led by Boston University, is funded by various government agencies and foundations, including the United States — United States Department of Health and Human Services, Wellcome Trust, and the Bill & Melinda Gates Foundation, among others.

Entities Involved

ngo

CARB-X

CARB-X awarded US$2.6 million in funding to AdJane to advance the development of a vaccine candidate for gonorrhea, continuing its mission to combat antibiotic-resistant bacteria.

Importance 90.0 Sentiment 50.0

per

Richard Alm

Richard Alm, interim Chief of R&D at CARB-X, commented on the increasing complexity of gonorrhea management and the potential of AdJane's approach.

Importance 20.0 Sentiment 0.0

per

Anita Gashi

Anita Gashi, Managing Director of AdJane, expressed gratitude for the CARB-X award and highlighted the potential of AdJane's nOMV platform.

Importance 20.0 Sentiment 0.0

govactor

Italy — Ministry of Economy and Finance (Italy)

Importance 0.0 Sentiment 0.0